(Q33528162)

English

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Anna Sapino

7

0 references

Massimo Aglietta

object named as

Massimo Aglietta

9

0 references

8

object named as

Giuseppe Viale

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Filippo Montemurro

object named as

Filippo Montemurro

10

1 reference

ORCID Public Data File 2021

author name string

Stefania Redana

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Michela Donadio

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Franco Nolè

3

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Maria Elena Jacomuzzi

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Alessandra Beano

5

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Rossella Martinello

6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

0 references

publication date

1 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-10-28

0 references

A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Trastuzumab-based combination therapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2835645

21 June 2018

Oral vinorelbine: feasibility and safety profile.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-28

21 January 2018

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-28

21 January 2018

A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-28

21 January 2018

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-28

21 January 2018

Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination

1 reference

https://pubmed.ncbi.nlm.nih.gov/20122160

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20122160

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20122160

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-10-28

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33528162&oldid=1951838951"